Active	Status	Sponsor type	Region	Phase	Filter
29 Active 0 Inactive 29 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

29 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cheng, Zhifeng
EFFECT, NCT05902078: Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis	Recruiting	4	300	RoW	Eldecalcitol capsules, Edirol, Calcitriol capsules, Haidewei	Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Chugai Pharma China Co., Ltd.	Low Bone Mineral Density, Postmenopausal Osteoporosis	06/25	12/25
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes	Recruiting	3	424	RoW	Victoza®., Metformin Hydrochloride, TQZ2451	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Type 2 Diabetes	12/21	12/21
RECAM, NCT04807348: Chiglitazar Added to Metformin for Type 2 Diabetes	Completed	3	533	RoW	Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage	Chipscreen Biosciences, Ltd.	Type 2 Diabetes	02/23	02/23
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus	Recruiting	3	672	RoW	PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo	PegBio Co., Ltd.	Type 2 Diabetes Mellitus (T2DM)	11/23	04/25
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes	Active, not recruiting	3	408	RoW	HTD1801, berberine ursodeoxycholate, Placebo	HighTide Biopharma Pty Ltd	T2DM (Type 2 Diabetes Mellitus)	03/25	09/25
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin	Active, not recruiting	3	551	RoW	HTD1801, berberine ursodeoxycholate, Placebo	HighTide Biopharma Pty Ltd	Type 2 Diabetes Mellitus	03/25	12/25
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin	Recruiting	3	888	Europe, US, RoW	Orforglipron, LY3502970, Dapagliflozin	Eli Lilly and Company	Type 2 Diabetes	10/25	10/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time	Completed	3	928	Europe, Canada, Japan, US, RoW	Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec	Eli Lilly and Company	Diabetes, Type 2 Diabetes	04/24	04/24
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture	Completed	3	514	RoW	HLX14, Prolia®	Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.	Postmenopausal	12/23	07/24
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	Completed	3	257	RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases	07/24	07/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight	Recruiting	3	600	Europe, Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	OSA, Overweight or Obesity	11/26	01/27
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone	Active, not recruiting	3	520	Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Type 2 Diabetes	04/25	04/25
NCT05963022: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)	Completed	3	168	RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Type 2 Diabetes	10/24	10/24
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes	Active, not recruiting	3	1500	Europe, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Type 2 Diabetes	08/25	08/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	Active, not recruiting	3	1576	Japan, US, RoW	Orforglipron, LY3502970, Semaglutide	Eli Lilly and Company	Type 2 Diabetes	09/25	09/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities	Active, not recruiting	3	3000	Europe, Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Overweight or Obesity	07/25	07/27
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee	Active, not recruiting	3	405	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Overweight, Osteo Arthritis Knee	02/26	03/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight	Active, not recruiting	3	2300	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea	04/26	05/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight	Active, not recruiting	3	1000	Europe, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea	05/26	05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events	Completed	2	233	Europe, Japan, US, RoW	LY3473329, Placebo	Eli Lilly and Company	Lipoprotein Disorder	03/24	03/24
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus	Not yet recruiting	2	318	RoW	HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Type 2 Diabetes	04/25	04/25
NCT06118021: A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects	Recruiting	2	200	RoW	HS-20094, HS-20094 injection, Placebo, Placebo injection	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Overweight and Obesity	08/24	10/24
NCT06606483: A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight	Not yet recruiting	2	300	RoW	MDR-001, Placebo	MindRank AI Ltd	Obesity, Overweight and Obesity	07/25	09/25
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease	Recruiting	2	320	RoW	SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan	Shanghai Pharmaceuticals Holding Co., Ltd	Diabetic Kidney Disease	06/25	06/25
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain	Active, not recruiting	2	145	Europe, Canada, Japan, US, RoW	GSK3858279, Placebo	GlaxoSmithKline	Pain	10/24	01/25
NCT06606509: The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).	Not yet recruiting	N/A	1000	RoW	Continuous Glucose Monitoring System (GX-01S)	Nanjing First Hospital, Nanjing Medical University	Type1 Diabetes Mellitus	10/26	06/27
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture	Recruiting	N/A	2478	RoW	Denosumab, Teriparatide	Peking Union Medical College Hospital	Osteoporotic Fractures	09/26	09/26